Pharmaceuticals and the Developing World
Bibliographic Data
| ID | 4030243 |
|---|---|
| Authors | Michael Kremer (0000-0002-4382-817X, Professor of Economics, Harvard University, Cambridge, Massachusetts, Senior Fellow, The Brookings Institution, Washington, D.C., and Research Fellow, National Bureau of Economic Research, Cambridge, Massachusetts., corresponding author) |
| Year | 2002 |
| Volume | 16 |
| Issue | 4 |
| Pages | 67-90 |
| Publication date | 2002-11-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | The Journal of Economic Perspectives (JOURNAL) |
| Journal identifiers | ISSN: 0895-3309 • E-ISSN: 1944-7965 |
| Publisher | American Economic Association (PUBLISHER • US) |
| DOI | 10.1257/089533002320950984 |
| PMID | 15179979 |
| OpenAlex | W2143906613 |
| Language | EN |
| Citations received | 24 |
| References cited | 17 |
Pharmaceuticals have greatly improved health in developing countries, but many people in developing countries do not obtain even inexpensive pharmaceuticals and little pharmaceutical R&D is oriented toward products needed by developing countries, such as a malaria vaccine. Access to existing products could be improved by facilitating differential pricing, for example by subsidizing donation programs, and reforming health care delivery. R&D incentives could be improved if rich countries or international organization committed to purchase needed products when they are developed and make them available to the poor
Business · Developed country · Developing country · Donation · Economic growth · Economics · Environmental health · Incentive · International trade · Market economy · Public economics · Subsidy · Health Systems, Economic Evaluations, Quality of Life · Intellectual Property and Patents · Medicine · Pharmaceutical Economics and Policy
Alternate paths to economic development
Science of Uncertainty
Why Working from Home Will Stick
Compulsory Licensing
Market Size in Innovation
Beyond Liberal Egalitarianism
Financial liberalization and the geography of poverty
Social Character of Science and Its Connection to Epistemic Reliability
Trade in health products and population health
Pharmaceutical companies and access to medicines – social integration and ethical CSR resolution of a global public choice problem
Good Law to Fight Bad Bugs
Health Expenditures and Global Inequalities in Longevity
Health policy, price regulation, and innovation
Public health insurance and pharmaceutical innovation
Compulsory licensing, price controls, and access to patented foreign products
Access to medicines, market failure and market intervention
Disease burden metrics and the innovations of leading pharmaceutical companies
From Free Entry to Patent Protection
Investments in Pharmaceuticals Before and After TRIPS
What Drives Donor Funding in Population Assistance Programs? Evidence from OECD Countries
The Determinants of Mortality
Prices, Patents and Access to Drugs
Patents and Innovation
Old Inequalities, New Disease
Market Size in Innovation
The Role of Wages and Auditing during a Crackdown on Corruption in the City of Buenos Aires
New Pills for Poor People? Empirical Evidence after Gatt
The Estimation of Prewar Gross National Product
Estimating Real Income in the United States from 1888 to 1994
The Changing Relation between Mortality and level of Economic Development
Anthropology and International Health
| Unique citing works | 24 |
|---|---|
| Citations per year | 1,09 |
| Citation span | 2004 - 2023 (20) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 22 |